Sensus Healthcare (NASDAQ:SRTS) is set to issue its Q2 2019 quarterly earnings data after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter.
Sensus Healthcare (NASDAQ:SRTS) last released its earnings results on Thursday, May 9th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.11). Sensus Healthcare had a negative return on equity of 13.34% and a negative net margin of 11.65%. The firm had revenue of $5.44 million for the quarter, compared to analyst estimates of $7.81 million. On average, analysts expect Sensus Healthcare to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
SRTS stock traded down $0.03 during trading on Tuesday, reaching $5.05. 110 shares of the stock were exchanged, compared to its average volume of 13,284. Sensus Healthcare has a twelve month low of $4.75 and a twelve month high of $9.23. The firm has a market capitalization of $84.24 million, a P/E ratio of -36.07 and a beta of -0.21. The business’s 50 day simple moving average is $5.31.
A number of equities research analysts have weighed in on SRTS shares. ValuEngine downgraded Sensus Healthcare from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Alliance Global Partners downgraded Sensus Healthcare from a “buy” rating to a “neutral” rating in a report on Friday, May 10th. Maxim Group reaffirmed a “buy” rating and set a $11.00 price objective on shares of Sensus Healthcare in a report on Friday, May 10th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Sensus Healthcare in a report on Monday, May 13th. Finally, TheStreet downgraded Sensus Healthcare from a “c-” rating to a “d+” rating in a report on Wednesday, May 22nd. One analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $9.50.
About Sensus Healthcare
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Recommended Story: Is the QQQ ETF safe?
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.